PF-03814735
PF-03814735 is a potent, orally available, ATP-competitive and reversible aurora A and aurora B inhibitor with IC50s of 0.8 and 0.5 nM, respectively.
Product Specifications
CAS Number
942487-16-3
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Aurora Kinase; VEGFR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PF-03814735.html
Purity
99.45
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(CNC(C)=O)N1[C@@H]2C3=C(C=C(NC4=NC(NC5CCC5)=C(C(F)(F)F)C=N4)C=C3)[C@H]1CC2
Molecular Formula
C23H25F3N6O2
Molecular Weight
474.48
Precautions
H315, H319, H335
References & Citations
[1]Jani JP, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther. 2010 Apr;9 (4) :883-94.|[2]Hook KE, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther. 2012 Mar;11 (3) :710-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Aurora A; Aurora B; VEGFR1/Flt-1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680953-100 1x 100 µL
Muscle Specific Actin (MSA/953), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC472595-500 1x 500 µL
PAX5 / BSAP (Early B-Cell Marker) (PAX5/2595), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
